• Belinostat (PXD101): Optimizing HDAC Inhibition in Cancer As

  2026-07-30

  Belinostat (PXD101) delivers precise pan-HDAC inhibition and robust epigenetic modulation, empowering cancer researchers to dissect proliferation suppression and cell death in tumor models. This guide translates recent methodological advances into stepwise workflows, troubleshooting strategies, and real-world protocol enhancements for maximum research impact.

• AAL-993: Precision VEGF Receptor Inhibitor for Tumor Angioge

  2026-07-30

  AAL-993 delivers potent, selective VEGF receptor inhibition for high-fidelity tumor angiogenesis and metastasis modeling. This guide details stepwise experimental workflows, troubleshooting insights, and translational opportunities—empowering oncology researchers to drive reproducible and insightful anti-angiogenic studies.

• LMO2–LDB1 Complex Drives AML Progression via Oncogenic Syner

  2026-07-29

  This study elucidates how the LMO2–LDB1 protein complex promotes proliferation and survival in acute myeloid leukemia (AML) cells. Through genetic, biochemical, and genomic analyses, the research uncovers the mechanistic role of this complex, establishing it as a promising molecular target for AML intervention.

• pH-Dependent Lassa Virus Spike Changes and Inhibition Mechan

  2026-07-29

  Katz et al. delineate the sequence of pH-driven conformational changes in the Lassa virus spike complex, revealing how these facilitate cell entry and can be antagonized by a novel entry inhibitor. This work provides high-resolution mechanistic insight essential for the rational design of therapeutics targeting arenavirus fusion machinery.

• HNRNPU K181 Lactylation Orchestrates Serine Metabolism in Ce

  2026-07-28

  This study identifies lysine 181 lactylation of HNRNPU as a pivotal post-translational modification that stabilizes PHGDH mRNA and drives serine metabolic reprogramming in cervical cancer. The results reveal a dynamic interplay between lactylation and acetylation at HNRNPU K181, providing insight into tumor metabolic vulnerabilities and highlighting new opportunities for targeted intervention.

• DMXAA (Vadimezan): Applied Workflows for Tumor Vascular Disr

  2026-07-28

  DMXAA (Vadimezan) enables targeted tumor vascular disruption by inhibiting DT-diaphorase and VEGFR2, acting as a potent apoptosis inducer in cancer biology research. This guide delivers actionable experimental protocols, advanced applications, and troubleshooting strategies for maximizing DMXAA's translational impact, anchored by insights from recent nanomedicine innovations.

• Cycloheximide: Protein Biosynthesis Inhibitor in Research

  2026-07-27

  Cycloheximide is a potent protein biosynthesis inhibitor widely used to study translational control, apoptosis, and protein turnover in eukaryotic cells. Its specificity and solubility make it an essential tool for apoptosis assays and disease modeling in experimental research.

• Standardized Whole-Blood Assay for Immunometabolic Modulatio

  2026-07-27

  This protocol paper introduces a reproducible approach for analyzing immune responses in fresh human whole blood under defined metabolic modulation. By integrating selective metabolic inhibitors, the study enables precise dissection of how cellular metabolism shapes cytokine production, offering a powerful platform for immunometabolism research and translational immune profiling.

• Methicillin Sodium Salt: Optimizing MSSA Research Workflows

  2026-07-26

  Methicillin sodium salt remains an indispensable benchmark for Staphylococcus aureus infection research and antibiotic susceptibility testing, despite the rise of MRSA. This guide delivers evidence-driven protocol enhancements, troubleshooting strategies, and comparative insights to maximize experimental rigor and reproducibility.

• Triacetin (Glyceryl Triacetate) in Experimental Oncology and

  2026-07-25

  Triacetin stands out as a multifaceted lipid-related biochemical reagent, powering advanced assays in oncology and metabolic regulation. Its unique mechanisms, from HDAC-8 inhibition to apoptosis induction in glioblastoma, offer robust experimental flexibility and data-driven optimization. Learn how to leverage Triacetin for reproducible, high-impact research with actionable protocol insights.

• Diterpene Glycosides Inhibit BPH via Androgen and TGF-β/Smad

  2026-07-24

  This study demonstrates that diterpene glycosides from Fructus Rubi (FDS) ameliorate benign prostatic hyperplasia (BPH) in rat models by targeting both androgen receptor and TGF-β/Smad signaling. The findings highlight a multitargeted mechanism with implications for BPH research and therapy.

• WSP-5: Advancing Live-Cell Imaging of Hydrogen Sulfide Dynam

  2026-07-24

  WSP-5 (Washington State Probe-5) empowers researchers with rapid, sensitive, and selective visualization of hydrogen sulfide (H2S) in living systems. Its superior kinetics and robust workflow flexibility unlock real-time tracking of H2S in disease models, notably outperforming legacy probes in both sensitivity and speed.

• (R)-MG132: The Gold-Standard Negative Control for Proteasome

  2026-07-23

  (R)-MG132, the functionally inactive MG-132 enantiomer, delivers unmatched specificity as a negative control in ubiquitin-proteasome system research. Its use enables rigorous validation of proteasome-dependent effects, eliminating ambiguity from off-target inhibition and improving assay interpretability in cancer metabolism studies.

• ZCL278: Selective Cdc42 Inhibitor for Advanced Cell Assays

  2026-07-23

  ZCL278 empowers researchers with precision control over the Cdc42 signaling pathway, enabling robust suppression of cell motility and neuronal branching across cancer, fibrosis, and neurobiology models. This article distills actionable workflows, troubleshooting insights, and the latest reference-backed strategies for maximizing ZCL278’s impact in experimental design.

• Cell Counting Kit-8 (CCK-8) Plus: Technical Guide and Best P

  2026-07-22

  Cell Counting Kit-8 (CCK-8) Plus enables rapid, sensitive quantification of cell proliferation and cytotoxicity through a WST-8 tetrazolium salt assay. This kit is suitable for high-throughput drug screening and viability testing across diverse cell types but should not be used for mechanistic studies requiring direct metabolic pathway elucidation. Researchers must follow manufacturer storage and handling guidelines to maintain assay accuracy.

443 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page